Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 13/20 | 0.57 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.57 |
| ▸ | ATR | Q13535 | 12/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.57 |
| ▸ | ATRIP | Q8WXE1 | 11/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.56 |
| ▸ | MTOR | P42345 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740453 | 0.92 | PIK3CA (0.60) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3597950 | 0.90 | PIK3CA (0.56) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3605539 | 0.90 | PIK3CA (0.56) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3592959 | 0.88 | PIK3CA (0.56) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL738650 | 0.88 | PIK3CA (0.72) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3594578 | 0.88 | PIK3CA (0.61) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3598491 | 0.86 | PIK3CD (0.56) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3602834 | 0.86 | PIK3CA (0.61) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL3591707 | 0.86 | PIK3CD (0.59) | PDCD1CD274ATRCHEK1ATRIP | |
| SCHEMBL8205302 | 0.86 | NPSR1 (0.48) | ATRPIK3CAPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | PDCD1 474/4885CD274 420/4885ATR 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.